57 Top Scientists Explain How Future Vaccine Deaths May Be Indistinguishable From COVID Deaths

Joined
Apr 11, 2010
Messages
2,957

Lots of scence but possibly the most important thing you will ever read, and understand.

https://coronanews123.wordpress.com...y-be-indistinguishable-from-new-covid-deaths/


Corona News comment: Last April 2021, a former chief science officer and vice president for Pfizer’s respiratory illness research division said, given the great numbers of numbers of “demonstrably false,” repetitious information now being given by governments and media, he had no choice to conclude that the COVID crisis may be part of a “massive depopulation” program. Long before that, scientists such as Dr. Judy Mikovits predicted up to 50 million Americans dead as a result of poorly-tested, mass vaccinations within a few years. The common thread is that it will all be blamed not on the mRNA injections, but on COVID “variants” and the “unvaccinated.” Even Facebook founder Mark Zuckerberg, who actively censors any questions about mRNA “vaccine” safety, was shown in a leaked video admitting that long-term side-effects were unknown. USA Today has reported that Facebook will not be requiring its employees to take the shots.

The following is reprinted from NOQReport, “57 leading scientists, doctors, and public policy experts call for IMMEDIATE HALT to Covid vaccine programs.” Critical passages have been bolded for ease of reading for the time-constrained reader.

May 8, 2021

There are two certainties about the Covid-19 vaccines being mass-distributed around the world. The first is that governments and the vast majority of mainstream media are pushing with as much ferocity as they can muster for these experimental drugs to be injected into as many people as possible. The second is that those who are brave enough to face the scorn that comes with asking serious questions about the vaccines are absolutely necessary components of our ongoing fight to spread the truth.

NOQ Report received an advanced copy of the manuscript in preprint below. It has been prepared by nearly five dozen highly respected doctors, scientists, and public policy experts from across the globe to be urgently sent to world leaders as well as all who are associated with the production and distribution of the various Covid-19 vaccines in circulation today.

There are still far too many questions about the safety, efficacy, and necessity of the Covid-19 vaccines that have not been addressed. This study is a bombshell that should resonate with all regardless of one’s perspectives on these vaccines. There are not enough citizens asking questions at all. Most are simply doing as world governments are instructing as if they have earned our blind trust. They have not. This manuscript represents a step towards accountability and the free flow of information regarding this extraordinarily important topic. Please read and share widely. – NOQ Report Editors
-------

Abstract
Since the start of the COVID-19 outbreak, the race for testing new platforms designed to confer immunity against SARS-CoV-2, has been rampant and unprecedented, leading to emergency authorization of various vaccines. Despite progress on early multidrug therapy for COVID-19 patients, the current mandate is to immunize the world population as quickly as possible. The lack of thorough testing in animals prior to clinical trials, and authorization based on safety data generated during trials that lasted less than 3.5 months, raise questions regarding the safety of these vaccines.

The recently identified role of SARS-CoV-2 glycoprotein Spike for inducing endothelial damage characteristic of COVID-19, even in absence of infection, is extremely relevant given that most of the authorized vaccines induce the production of Spike glycoprotein in the recipients. Given the high rate of occurrence of adverse effects, and the wide range of types of adverse effects that have been reported to date, as well as the potential for vaccine-driven disease enhancement, Th2-immunopathology, autoimmunity, and immune evasion, there is a need for a better understanding of the benefits and risks of mass vaccination, particularly in the groups that were excluded in the clinical trials.

Despite calls for caution, the risks of SARS-CoV-2 vaccination have been minimized or ignored by health organizations and government authorities. We appeal to the need for a pluralistic dialogue in the context of health policies, emphasizing critical questions that require urgent answers if we wish to avoid a global erosion of public confidence in science and public health.

Introduction
Since COVID-19 was declared a pandemic in March 2020, over 150 million cases and 3 million deaths have been reported worldwide. Despite progress on early ambulatory, multidrug-therapy for high-risk patients, resulting in 85% reductions in COVID-19 hospitalization and death [1], the current paradigm for control is mass-vaccination. While we recognize the effort involved in development, production and emergency authorization of SARS-CoV-2 vaccines, we are concerned that risks have been minimized or ignored by health organizations and government authorities, despite calls for caution [2-8].

Vaccines for other coronaviruses have never been approved for humans, and data generated in the development of coronavirus vaccines designed to elicit neutralizing antibodies show that they may worsen COVID-19 disease via antibody-dependent enhancement (ADE) and Th2 immunopathology, regardless of the vaccine platform and delivery method [9-11]. Vaccine-driven disease enhancement in animals vaccinated against SARS-CoV and MERS-CoV is known to occur following viral challenge, and has been attributed to immune complexes and Fc-mediated viral capture by macrophages, which augment T-cell activation and inflammation [11-13].

In March 2020, vaccine immunologists and coronavirus experts assessed SARS-CoV-2 vaccine risks based on SARS-CoV-vaccine trials in animal models. The expert group concluded that ADE and immunopathology were a real concern, but stated that their risk was insufficient to delay clinical trials, although continued monitoring would be necessary [14].

While there is no clear evidence of the occurrence of ADE and vaccine-related immunopathology in volunteers immunized with SARS-CoV-2 vaccines [15], safety trials to date have not specifically addressed these serious adverse effects (SAE). Given that the follow-up of volunteers did not exceed 2-3.5 months after the second dose [16-19], it is unlikely such SAE would have been observed. Despite92 errors in reporting, it cannot be ignored that even accounting for the number of vaccines administered, according to the US Vaccine Adverse Effect Reporting System (VAERS), the number of deaths per million vaccine doses administered has increased more than 10-fold. We believe there is an urgent need for open scientific dialogue on vaccine safety in the context of large-scale immunization.

In this paper, we describe some of the risks of mass vaccination in the context of phase 3 trial exclusion criteria and discuss the SAE reported in national and regional adverse effect registration systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass vaccination.

SARS-CoV-2 phase 3 trial exclusion criteria

With few exceptions, SARS-CoV-2 vaccine trials excluded the elderly [16-19], making it impossible to identify the occurrence of post-vaccination eosinophilia and enhanced inflammation in elderly people. Studies of SARS-CoV vaccines showed that immunized elderly mice were at particularly high risk of life-threatening Th2 immunopathology [9,20]. Despite this evidence and the extremely limited data on safety and efficacy of SARS-CoV-2 vaccines in the elderly, mass-vaccination campaigns have focused on this age group from the start. Most trials also excluded pregnant and lactating volunteers, as well as those with chronic and serious conditions such as tuberculosis, hepatitis C, autoimmunity, coagulopathies, cancer, and immune suppression [16-29], although these recipients are now being offered the vaccine under the premise of safety.

Another criterion for exclusion from nearly all trials was prior exposure to SARS-CoV-2. This is unfortunate as it denied the opportunity of obtaining extremely relevant information concerning post-vaccination ADE in people that already have anti-SARS-Cov-2 antibodies. To the best of our knowledge, ADE is not being monitored systematically for any age or medical condition group currently being administered the vaccine. Moreover, despite a substantial proportion of the population already having antibodies [21], tests to determine SARS-CoV-2-antibody status prior to administration of the vaccine are not conducted routinely.



Will serious adverse effects from the SARS-CoV-2 vaccines go unnoticed?

COVID-19 encompasses a wide clinical spectrum, ranging from very mild to severe pulmonary pathology and fatal multi-organ disease with inflammatory, cardiovascular, and blood coagulation dysregulation [22-24]. In this sense, cases of vaccine-related ADE or immunopathology would be clinically-indistinguishable from severe COVID-19 [25].

Furthermore, even in the absence of SARS-CoV-2 virus, Spike glycoprotein alone causes endothelial damage and hypertension in vitro and in vivo in Syrian hamsters by down-regulating angiotensin-converting enzyme 2 (ACE2) and impairing mitochondrial function [26].

Although these findings need to be confirmed in humans, the implications of this finding are staggering, as all vaccines authorized for emergency use are based on the delivery or induction of Spike glycoprotein synthesis. In the case of mRNA vaccines and adenovirus-vectorized vaccines, not a single study has examined the duration of Spike production in humans following vaccination. Under the cautionary principle, it is parsimonious to consider vaccine-induced Spike synthesis could cause clinical signs of severe COVID-19, and erroneously be counted as new cases of SARS-CoV-2 infections
.
FULL LETTER https://coronanews123.wordpress.com...y-be-indistinguishable-from-new-covid-deaths/
 
Last edited:
In this sense, cases of vaccine-related ADE or immunopathology would be clinically-indistinguishable from severe COVID-19 [25].

It's called enhancement for a reason. It enhances a subsequent COVID infection, thus it will be unprovable and indistinguishable from a bad case of COVID. Very convenient.
 
I suspect they will blame the deaths on what they call a variant.
 
Is this published to coronanews123 because no journal would take it?

I can’t vouch for that website or the full article, but “vaccine induced enhancement”, also known by various other labels and acronyms such as antibody-dependent enhancement (ADE), is very well known.

Even Fauci warned about it at one point:

"I'm cautiously optimistic that we will get a vaccine," Dr. Anthony Fauci, the National Institutes of Health's director for infectious diseases, said in an interview this week. "The thing that's sobering is that it's not a vaccine we're going to have next month, so we're going to have to tough it out through this evolution."

Early efforts to develop a SARS vaccine in animal trials were plagued by a phenomenon known as "vaccine-induced enhancement," in which recipients exhibit worse symptoms after being injected — something Fauci said researchers must be mindful of as they work to quickly develop a vaccine to protect against COVID-19.
...
https://www.nbcnews.com/health/heal...s-vaccine-years-ago-then-money-dried-n1150091

My take from last year:

Beyond initial adverse reactions, an important test of the new vaccines will be when people are exposed to the real virus in the wild. It may take years, and it will never be conclusive. An adverse reaction (or vaccine induced enhancement) a year later will probably be blamed on a new variant of the virus.

And yes, Twitter, Facebook and the media-pharma complex are suppressing and censoring any discussion of this topic.

Here’s a central thread on the subject:

http://www.ronpaulforums.com/showth...accines-quot-vaccine-induced-enhancement-quot
 
My take from last year:
The whole story is so ridiculous... even when you believe that there is a "pandemic" caused by some mutated coronavirus... this couldn't be reason to emergency approve experimental vaccines without proper medical trials.


Is this published to coronanews123 because no journal would take it?
That paper won't be published in any of the "reputable" scientific journals.
The following looks like a more credible article, but is much, much longer...

Firestarter said:
This is from a recent literature review of some of the reasons that the experimental COVID vaccines shouldn't have been emergency approved. My main problem with the paper is overlength (40+ pages).
Sadly missing is the Pfizer study that showed that the COVID vaccine suppressed the immune system for 6 to 8 days from the original post in this thread (there wouldn't be some sort of cover-up would it?)...


One thing I learned from the paper is the reason that the COVID mRNA vaccines have to be stored at so incredibly low temperatures (70 degrees Celsius for the Pfizer vaccine), is gene-edited vaccines are highly unstable, because the mRNA in vaccines breaks down.

Another interesting tidbit of information is that instead of the "normal" adjuvants that are intentionally added to vaccines to make them extra damaging for your health (to "boost" immune response - no joke!), new experimental never before used polyethylene glycol (PEG) have been used for adjuvant.
In animal studies it has been shown that complement activation is responsible for both anaphylaxis and cardiovascular collapse, and injected PEG activates multiple complement pathways in humans as well. The authors of one study conclude by noting that “This cascade of secondary mediators substantially amplifies effector immune responses and may induce anaphylaxis in sensitive individuals. Indeed, recent studies in pigs have demonstrated that systemic complement activation (e.g., induced following intravenous injection of PEGylated liposomes) can underlie cardiac anaphylaxis where C5a played a causal role.” (Hamad et al., 2008) It is also important to note that anaphylactoid shock in pigs occurred not with first injected exposure, but following second injected exposure (Kozma et al., 2019).

The presence of antibodies against PEG is widespread in the population (Zhou et al., 2020). Yang and Lai (2015) found that around 42% of blood samples surveyed contained anti-PEG antibodies, and they warn that these could have important consequencesfor any PEG-based therapeutics introduced. Hong et. al. (2020) found anti-PEG antibodies with a prevalence up to 72% in populations with no prior exposure to PEG-based medical therapy. Lila et. al. (2018) note that the “existence of such anti-PEG antibodies has been intimately correlated with an impairment of therapeutic efficacy in tandem with the development of severe adverse effects in several clinical settings employing PEGylated-based therapeutics.”

Here's the full study: https://ijvtpr.com/index.php/IJVTPR/article/view/23/36
Immune-deficiency-cover-up/page2
 
Back
Top